ValiRx - ValiSeek Clinical Update, VAL401
VAL Tue, 16 Jan 2018, 07:10am GMT
Dr Suzy Dilly provides an update on the clinical progress and results of VAL401, the anti-cancer compound developed by ValiSeek, the joint venture between ValiRx and Tangent Reprofiling Limited. Further positive data has been released and shows that the VAL401 treatment has a measurable improvement on patient quality of Life, in addition to a positive impact on the disease.
Suzanne Dilly
CEO, ValiSeek Limited
Dr Cathy Tralau-Stewart, Chief Scientific Officer
Thu, 21 Mar 2024, 7:05am GMT
Dr Cathy Tralau-Stewart, Chief Scientific Officer
Mon, 12 Feb 2024, 3:00pm GMT
Suzanne Dilly, Chief Executive Officer
Tue, 5 Dec 2023, 2:00pm GMT
Suzanne Dilly, Chief Executive Officer
Thu, 28 Sep 2023, 7:00am BST
Suzanne Dilly, Chief Executive Officer
Wed, 14 Jun 2023, 3:00pm BST
Suzanne Dilly, Chief Executive Officer
Tue, 31 Jan 2023, 2:28pm GMT
Suzanne Dilly, Chief Executive Officer
Thu, 26 Jan 2023, 1:32pm GMT
Professor Martin Ulmschneider, Head of Department of Chemistry - Kings...
Fri, 28 Oct 2022, 4:45pm BST
Suzanne Dilly, Chief Executive Officer
Thu, 29 Sep 2022, 4:27pm BST
Suzanne Dilly, Chief Executive Officer
Thu, 14 Jul 2022, 1:30pm BST
Suzanne Dilly, Chief Executive Officer
Thu, 30 Jun 2022, 11:00am BST
ValiRx - Board Members, ValiRx PLC
Wed, 6 Apr 2022, 5:00pm BST
Suzanne Dilly, Chief Executive Officer
Wed, 23 Mar 2022, 12:56pm GMT
Suzanne Dilly, Chief Executive Officer
Wed, 5 Jan 2022, 12:00pm GMT
Suzanne Dilly, Chief Executive Officer
Mon, 20 Dec 2021, 12:20pm GMT
Suzanne Dilly, Chief Executive Officer
Fri, 26 Nov 2021, 4:48pm GMT
Suzanne Dilly, Chief Executive Officer
Tue, 2 Nov 2021, 5:00pm GMT
Suzanne Dilly, Chief Executive Officer
Fri, 28 May 2021, 12:30pm BST
